中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

235 records (took 0.036 seconds)

    C-TERMINAL FRAGMENT OF TETANUS TOXIN (HC) FOR TREATMENT OF DEPRESSION
    72.
    发明申请
    C-TERMINAL FRAGMENT OF TETANUS TOXIN (HC) FOR TREATMENT OF DEPRESSION 审中-公开

    公开(公告)号：WO2021236430A1

    公开(公告)日：2021-11-25

    申请号：PCT/US2021/032370

    申请日：2021-05-14

    Applicant: HOWARD UNIVERSITY

    Inventor： TIZABI, Yousef

    IPC: A61K38/48 ,  A61K48/00

    Abstract: C-terminal domain of the heavy chain of tetanus toxin (Hc-TeTx) provides therapeutic effects in motor impairments associated with Parkinson disease (PD), and provides long lasting antidepressant effects, thus useful in treating and mitigating depression, particularly PD-depression co-morbid condition. A method for treating or mitigating depression, including administrating an effective amount of C-terminal domain of the heavy chain of tetanus toxin (Hc-TeTx) to a subject in need thereof. A method for treating or mitigating motor impairments associated with Parkinson's disease (PD), including administrating an effective amount of C-terminal domain of the heavy chain of tetanus toxin (Hc-TeTx) to a subject in need thereof.

    MICROCARRIERS, MATRICES AND SCAFFOLDS FOR CULTURING MAMMALIAN CELLS AND METHODS OF MANUFACTURE
    74.
    发明申请
    MICROCARRIERS, MATRICES AND SCAFFOLDS FOR CULTURING MAMMALIAN CELLS AND METHODS OF MANUFACTURE 审中-公开
    培养MAMMALIAN细胞的微阵列，基质和标准物及其制备方法

    公开(公告)号：WO2016154048A1

    公开(公告)日：2016-09-29

    申请号：PCT/US2016/023248

    申请日：2016-03-18

    Applicant: HOWARD UNIVERSITY

    Inventor： MITCHELL, James W. ,  YANG, Dazhi

    IPC: A61K31/715 ,  A61K31/717 ,  A61K31/738 ,  B01J20/24

    CPC classification number: C08B15/005 ,  C08B15/02 ,  C08B15/06 ,  C08H1/00 ,  C12N5/0075

    Abstract: Microcarriers, matrices and scaffolds for growing mammalian cells are provided which include copolymer particles and matrices comprising of polysaccharide-polyamine copolymers. The copolymeric particles and matrices have a pore size of at least 50 microns and permit the mammalian cells to grow both on an exterior surface of the particles and matrices and within an interior of the particles and matrices. Methods for making such microcarriers, matrices and scaffolds, and compositions are also provided. Methods for growing mammalian cells utilizing such microcarriers, matrices and scaffolds and compositions are also provided.

    Abstract translation: 提供了用于生长哺乳动物细胞的微载体，基质和支架，其包括共聚物颗粒和由多糖 - 多胺共聚物组成的基质。 共聚物颗粒和基质具有至少50微米的孔径，并允许哺乳动物细胞在颗粒和基质的外表面上以及在颗粒和基质内部生长。 还提供了制备这种微载体，基质和支架以及组合物的方法。 还提供了使用这种微载体生长哺乳动物细胞的方法，基质和支架和组合物。

    BENZENDE SULFONAMIDE DERIVATIVES AS HIV INTEGRASE INHIBITORS
    75.
    发明申请
    BENZENDE SULFONAMIDE DERIVATIVES AS HIV INTEGRASE INHIBITORS 审中-公开
    苯并噻吩衍生物作为艾滋病综合抑制剂

    公开(公告)号：WO2015130947A1

    公开(公告)日：2015-09-03

    申请号：PCT/US2015/017781

    申请日：2015-02-26

    Applicant: HOWARD UNIVERSITY

    Inventor： WANG, Xiang Simon

    IPC: A61P25/28 ,  A61P25/16

    CPC classification number: C07C311/41 ,  A61K31/18 ,  C07C311/18

    Abstract: There are provided methods for treating retroviral infection or inhibiting HIV integrase in target cells or in a patient involving administering to said target cells or to a patient in need of treatment an effective amount of at least one anti-viral compound having a disulfonamide scaffold according to formulae disclosed herein, and compositions comprising same.

    Abstract translation: 提供了用于治疗逆转录病毒感染或抑制靶细胞或涉及向所述靶细胞或需要治疗的患者施用有效量的至少一种具有二磺酰胺支架的抗病毒化合物的靶向细胞或病人的方法。 本文公开的配方和包含其的组合物。

    VOXEL-RESOLUTION MYOCARDIAL BLOOD FLOW ANALYSIS
    76.
    发明申请
    VOXEL-RESOLUTION MYOCARDIAL BLOOD FLOW ANALYSIS 审中-公开

    公开(公告)号：WO2015051256A1

    公开(公告)日：2015-04-09

    申请号：PCT/US2014/059062

    申请日：2014-10-03

    Applicant: HOWARD UNIVERSITY

    Inventor： ANDERSON, John M.M.

    IPC: A61B5/02

    CPC classification number: A61B6/503 ,  A61B5/026 ,  A61B6/037 ,  A61B6/507 ,  A61B6/5217 ,  G06F19/00 ,  G16H50/50

    Abstract: A myocardial blood flow analysis scan includes incorporating a pharmacological kinetic model with the standard factor analysis model where each time activity curve is assumed to be a linear combination of factor curves. Pharmacological kinetics based factor analysis of dynamic structures (K-FADS-II) model can be applied, whereby estimating factor curves in the myocardium can be physiologically meaningful is provided. Additional optional aspects include performing a discretization to transform continuous-time K-FADS-II model into a discrete-time K-FADS-II model and application of an iterative Improved Voxel-Resolution myocardial blood flow (IV-MBF) algorithm. Where the model is applied without assumption that a right ventricle tissue curve and a left ventricle tissue curve obey a particular mathematical relationship, a least squares objective function can be applied to obtain estimates for parameters of the pharmacological kinetic model by applying a majorize-minimize optimization technique to iteratively estimate the curves.

    Abstract translation: 心肌血流分析扫描包括将药理动力学模型与标准因子分析模型结合，其中每个活动曲线被假定为因子曲线的线性组合。 可以应用动态结构（K-FADS-II）模型的药理动力学因子分析，从而提供心肌中估计因子曲线的生理意义。 其他可选方面包括执行离散化以将连续时间的K-FADS-II模型转换为离散时间的K-FADS-II模型，并应用迭代改进的体素分辨率心肌血流（IV-MBF）算法。 在没有假设右心室组织曲线和左心室组织曲线遵循特定数学关系的情况下应用模型的情况下，可以应用最小二乘方目标函数以通过应用主要最小化优化来获得药理动力学模型参数的估计 迭代估计曲线的技术。

    METHOD OF INCREASING THE BIOAVAILABILITY OF AN HIV DRUG
    77.
    发明申请
    METHOD OF INCREASING THE BIOAVAILABILITY OF AN HIV DRUG 审中-公开
    增加艾滋病毒药物生物可利用性的方法

    公开(公告)号：WO2015035218A1

    公开(公告)日：2015-03-12

    申请号：PCT/US2014/054367

    申请日：2014-09-05

    Applicant: HOWARD UNIVERSITY

    Inventor： KARLA, Pradeep

    IPC: A61K31/00

    CPC classification number: A61K31/675 ,  A61K9/0034 ,  A61K9/06 ,  A61K31/47 ,  A61K31/4745 ,  A61K31/4985 ,  A61K45/06 ,  A61K2300/00

    Abstract: Methods and compositions are provided for reducing transmission and/or infection of HIV in a subject by increasing the bioavailability of a drug in the subject. The methods and compositions provided herein include an efflux transporter inhibitor and a drug effective for reducing the transmission and/or infection of HIV in a subject. The efflux transporter inhibitor is effective to reduce the efflux of the drug through at least one of P glycoprotein (Pgp), breast cancer resistant protein (BCRP), and multidrug resistant associated protein 1-9 (MRP1-9).

    Abstract translation: 提供了通过增加受试者中药物的生物利用度来减少受试者中HIV的传播和/或感染的方法和组合物。 本文提供的方法和组合物包括外排转运蛋白抑制剂和有效减少受试者中HIV传播和/或感染的药物。 外排转运蛋白抑制剂通过P糖蛋白（Pgp），乳腺癌耐药蛋白（BCRP）和多药耐药相关蛋白1-9（MRP1-9）中的至少一种有效减少药物的流出。

    APPARATUS AND METHOD OF FAULT DETECTION AND LOCATION DETERMINATION
    78.
    发明申请
    APPARATUS AND METHOD OF FAULT DETECTION AND LOCATION DETERMINATION 审中-公开
    装置和故障检测方法和位置确定

    公开(公告)号：WO2013169656A1

    公开(公告)日：2013-11-14

    申请号：PCT/US2013/039722

    申请日：2013-05-06

    Applicant: HOWARD UNIVERSITY

    Inventor： KIM, Charles J.

    IPC: G01R31/08 ,  G01R31/12 ,  G01R31/02

    CPC classification number: G01R31/083

    Abstract: A distance from a measurement point to a fault in a three-phase circuit is determined. The measurement point is located at an output of a power sub-station and the three phase circuit has a loop circuit having an associated net fault line current and a ground current. A derivative of the net fault line current of the loop circuit as measured from the measurement point is calculated. An uncompensated distance to the sub-cycle fault using at least the derivative of the net fault current is determined, and configured, to compensate for the ground current of the loop circuit. The compensation is applied to the uncompensated distance to produce a compensated distance to the sub-cycle fault.

    Abstract translation: 确定三相电路中从测量点到故障的距离。 测量点位于电力子站的输出端，并且三相电路具有具有相关联的净故障线电流和接地电流的回路电路。 计算从测量点测量的环路电路的净故障线电流的导数。 确定至少与净故障电流的导数对子周期故障的无补偿距离，并配置为补偿环路电路的接地电流。 补偿应用于无补偿距离，以产生到子周期故障的补偿距离。

    POLYLACTIDE AND CALCIUM PHOSPHATE COMPOSITIONS AND METHODS OF MAKING THE SAME
    79.
    发明申请
    POLYLACTIDE AND CALCIUM PHOSPHATE COMPOSITIONS AND METHODS OF MAKING THE SAME 审中-公开
    聚合物和磷酸钙组合物及其制备方法

    公开(公告)号：WO2013154705A1

    公开(公告)日：2013-10-17

    申请号：PCT/US2013/029858

    申请日：2013-03-08

    Applicant: HOWARD UNIVERSITY

    Inventor： WANG, Tongxin ,  MITCHELL, James W.

    IPC: C08K9/02 ,  C08K9/06

    CPC classification number: C08K3/32 ,  A61L27/12 ,  A61L27/18 ,  A61L27/58 ,  A61L2430/02 ,  C08K2003/325 ,  C08L67/04

    Abstract: A method is provided for synthesizing polylactide/calcium phosphate composites. In one form, the calcium phosphate material is protonated with an acid and after protonation, combined with a silane material to form an intermediate silanized calcium phosphate material. The intermediate silanized calcium phosphate material is then combined with a lactide material to form the polylactide/ calcium phosphate matrix material that has at least 1.3 times the tensile strength of a polylactide/calcium phosphate material prepared without combining the silane with the calcium phosphate material.

    Abstract translation: 提供了一种合成聚丙交酯/磷酸钙复合材料的方法。 在一种形式中，磷酸钙材料用酸质子化并且在质子化之后，与硅烷材料组合以形成中间体硅烷化磷酸钙材料。 然后将中间硅烷化磷酸钙材料与丙交酯材料组合以形成聚丙交酯/磷酸钙基质材料，其具有在不将硅烷与磷酸钙材料组合的情况下制备的聚丙交酯/磷酸钙材料的拉伸强度的至少1.3倍。

Patent Agency Ranking